<DOC>
	<DOCNO>NCT02597712</DOCNO>
	<brief_summary>A phase 2 , randomise , double-blind , out-patient trial determine YF476 safe effective treatment patient Barrett 's esophagus .</brief_summary>
	<brief_title>YF476 Barrett 's Esophagus</brief_title>
	<detailed_description />
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Aged &gt; 18 year , histologically confirm diagnosis Barrett 's esophagus ( BE ) without dysplasia . A prior endoscopy biopsy read indefinite dysplasia permit biopsy recent endoscopy prior study entry demonstrate BE without dysplasia . Minimum 1 cm circumferential Barrett 's mucosa endoscopy least 2 cm maximal contiguous extent Barrett 's mucosa , measure top gastric fold squamocolumnar junction ( Prague criterion C &gt; 1 , M C , M &gt; 2 ) . Proton pump inhibitor use least daily , least 12 month prior enrolment , stable dose PPI 3 month enrolment . Any PPI , dose , frequency allowable . ECOG performance status &lt; 2 Karnofsky &gt; 60 % Normal organ marrow function , define white blood cell &gt; 3 x 10e9 , absolute neutrophil count &gt; 1.5 x 10e9 , platelet &gt; 100 x 10e9 , creatinine &lt; 1.5 mg/dL , total bilirubin &lt; 1.5 mg/dL , AST &lt; 100 U/L , ALT &lt; 100 U/L . Use adequate contraception study , follow ; Postmenopausal woman must last menstrual period least 1 year ago . Premenopausal woman , sexuallyactive , must hysterectomy bilateral oophorectomy ; must use intrauterine device ( IUD ) , spermicide diaphragm , cap condom . Streroid contraceptives 'the pill ' allow unless combination one aforementioned barrier contraceptive method . Men must use condom spermicide . Willingness comply treatment followup procedure . Ability understand willingness sign write informed consent document . Up date ageappropriate cancer screen test , per American Cancer Society guideline , ( Columbia University ) , cancer screening test plan next 21 week . Histologically confirm BE highgrade dysplasia . Histologically confirm diagnosis invasive carcinoma esophagus . Histologically confirm BE lowgrade dysplasia diagnose least 2 expert gastrointestinal pathologist . Prior endoscopic therapy BE . Any history esophageal gastric surgery . History atrophic gastritis , pernicious anemia , ZollingerEllison syndrome . Participation trial IMP within previous 28 day . Prolonged QTc interval &gt; 450 msec . History allergic reaction attribute compound similar chemical composition YF476 . History baseline finding : diabetes mellitus require insulin therapy pancreatitis ( baseline amylase and/or lipase &gt; 2.0 x ULN ) hepatitis B , hepatitis C HIV malabsorption syndrome inability swallow retain oral medicine major surgery &lt; 28 day prior enrolment ECOG performance status &gt; 2 another cancer within 3 year except basal carcinoma skin cervical carcinoma insitu also , clinically significant uncontrolled major morbidity include limited : serious cardiac disease ( unstable angina , s/p myocardial infarction &lt; 1 month ) ; respiratory disease ( advanced COPD pulmonary fibrosis ) ; uncontrolled hypertension ; active systemic infection ; psychiatric illness/social situation would limit compliance study requirement . Certain medicine herbal remedy take 7 day start study drug . A history cancer &gt; 3 year time enrolment , patient date surveillance cancer ( base American Cancer Society guideline , Columbia University ) , evidence cancer time enrolment , surveillance test plan within 21 week enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>acid reflux</keyword>
	<keyword>intragastric pH</keyword>
	<keyword>gastrin</keyword>
	<keyword>hypergastrinemia</keyword>
</DOC>